Indivior (NASDAQ:INDV) Director Buys $27,427.25 in Stock

Indivior PLC (NASDAQ:INDV) Director Keith Humphreys bought 775 shares of the stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director directly owned 5,802 shares in the company, valued at approximately $205,332.78. This trade represents a 15.42% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Indivior Price Performance

Shares of Indivior stock traded down $0.35 during trading hours on Wednesday, reaching $35.85. The company had a trading volume of 1,097,072 shares, compared to its average volume of 1,460,802. The firm has a market cap of $4.48 billion, a PE ratio of 38.96 and a beta of 0.75. Indivior PLC has a one year low of $7.62 and a one year high of $38.00. The business has a fifty day simple moving average of $33.69 and a 200 day simple moving average of $25.59.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The business had revenue of $314.00 million for the quarter, compared to analysts’ expectations of $257.66 million. On average, research analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Analysts Set New Price Targets

INDV has been the subject of a number of recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Craig Hallum restated a “buy” rating and set a $41.00 target price on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price target (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Finally, Northland Securities set a $40.00 price objective on Indivior in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.71.

Institutional Investors Weigh In On Indivior

A number of large investors have recently added to or reduced their stakes in INDV. Mirae Asset Global Investments Co. Ltd. lifted its stake in Indivior by 16.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after purchasing an additional 666 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after buying an additional 1,013 shares in the last quarter. CWM LLC bought a new stake in Indivior in the 3rd quarter worth approximately $25,000. Quarry LP purchased a new stake in Indivior in the third quarter worth approximately $26,000. Finally, Raymond James Financial Inc. bought a new position in Indivior during the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.